Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 13Burkitt Lymphoma 9Lung Neoplasms 7Lymphoma, Non-Hodgkin 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myeloid, Acute 5Carcinoma, Non-Small-Cell Lung 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Hodgkin Disease 4Sarcoma, Ewing 3Recurrence 3Plasmablastic Lymphoma 3Multiple Myeloma 3Lymphoma, B-Cell 3Leukemia 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Plasma Cell 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Immunoblastic Lymphadenopathy 2HIV Infections 2Ganglioneuroblastoma 2Congenital Abnormalities 2Central Nervous System Neoplasms 2

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Etoposide × 30 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡